Reference number(s)
6393-C

Initial Prior Authorization with Quantity Limit Eohilia

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Eohilia	budesonide suspension

Indications

FDA-approved Indications

Eohilia is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).

Limitations of Use

Eohilia has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks.

Coverage Criteria

Eosinophilic Esophagitis (EoE)

Authorization may be granted when the patient has the diagnosis of eosinophilic esophagitis (EoE). [ACTION REQUIRED: Documentation is required for approval.] when ALL of the following criteria are met:

- The patient is 11 years of age or older
- The patient has a history of clinical symptoms of esophageal dysfunction (e.g., eating problems, abdominal pain, heartburn, dysphagia, vomiting, food impaction, weight loss) at baseline

Continuation of Therapy

Eosinophilic Esophagitis (EoE)

Authorization may be granted when the patient has the diagnosis of eosinophilic esophagitis (EoE). [ACTION REQUIRED: Documentation is required for approval.] when ALL of the following criteria are met:

- The patient is 11 years of age or older
- The patient has achieved or maintained a positive clinical response (e.g., improvement in symptoms of esophageal dysfunction, histologic remission on biopsy). [ACTION REQUIRED: Documentation is required for approval.]

Quantity Limits Apply

60 unit-dose packets per 25 days or 180 unit-dose packets per 75 days

The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

Duration of Approval (DOA)

- 6393-C: Initial therapy DOA: 6 months; Continuation of therapy DOA: 12 months

References

1. Eohilia [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; February 2024.
2. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed February 29, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 02/29/2024).
4. Dellon E, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). Am J Gastroenterol. 2013;108:679–692.

5. Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776-1786.

Document History

Written by: UM Development (DRS)

Date Written: 02/2024

Revised: 04/2024 (amended coverage criteria)

Reviewed: Medical Affairs: (CHART) 03/07/2024, 04/04/2024

External Review: 04/2024